SNUP

This brand name is authorized in Austria, Croatia, Germany, Hong Kong SAR China, Poland, Romania, Singapore.

Active ingredients

The drug SNUP contains one active pharmaceutical ingredient (API):

1	Xylometazoline UNII X5S84033NZ - XYLOMETAZOLINE HYDROCHLORIDE
	Xylometazoline acts directly on α-adrenoreceptors but does not act on β-receptors. When used topically as a nasal decongestant, xylometazoline acts rapidly and provides long-lasting relief. Onset of action is within minutes, the decongestant effect being prolonged and lasting for up to 10 hours.
	Read more about Xylometazoline

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
R01AA07	Xylometazoline	R Respiratory system → R01 Nasal preparations → R01A Decongestants and other nasal preparations for topical use → R01AA Sympathomimetics, plain
Discover more medicines within R01AA07

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
DE	Bundesinstitut für Arzneimittel und Medizinprodukte	04482651, 04482674, 04482680
HK	Department of Health Drug Office	62832
HR	Agencija za lijekove i medicinske proizvode	HR-H-098374942, HR-H-799955238
PL	Rejestru Produktów Leczniczych	100365810
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W63667001, W63667002, W63667003, W63667004, W63668001, W63668002, W63668003, W63668004
SG	Health Sciences Authority	15198P